Unresectable stage III non-small-cell lung cancer: lines of therapy

Cancer page →

4 standard-of-care settings across 3 lines and 3 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

Line	All comers	EGFR	Unfit / older
Locally advanced	·	2	·
Special situations	·	·	1
Other settings	1	·	·

Locally advanced

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
EGFR	Unresectable stage III, fit, no EGFR mutation	Concurrent platinum-based chemoradiation to 60 Gy with intensity-modulated radiotherapy, then durvalumab for up to a year in patients without progression (PACIFIC).	PACIFICDurvalumabChemoradiation (chemoradiotherapy, CRT)IMRT / IGRT (modern external beam)CisplatinCarboplatinEtoposidePemetrexedPaclitaxel / nab-paclitaxelConsolidation therapy	NCCN Guidelines: Non-Small Cell Lung Cancer	93
EGFR	Unresectable stage III, EGFR-mutated	Concurrent chemoradiation then osimertinib until progression (LAURA).	LAURAOsimertinibChemoradiation (chemoradiotherapy, CRT)	NCCN Guidelines: Non-Small Cell Lung Cancer	87

Special situations

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
Unfit / older	Unfit for concurrent treatment	Sequential chemotherapy then radiotherapy, or radiotherapy alone with a hypofractionated schedule; durvalumab afterwards where tolerated.	IMRT / IGRT (modern external beam)Hypofractionated radiotherapyDurvalumabCarboplatinPaclitaxel / nab-paclitaxel	NCCN Guidelines: Non-Small Cell Lung Cancer	93

Other settings

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Toxicity	Grading and steroid treatment of radiation and immune pneumonitis; oesophagitis supportive care; heart dose constraints in planning.	Radiation pneumonitis and lung fibrosisInterstitial lung disease (ILD) / pneumonitisIMRT / IGRT (modern external beam)Proton therapy	NCCN Guidelines: Non-Small Cell Lung Cancer	93

Sequence and caution pairings

CautionApproved

Caution: DXd ADC + agents with pneumonitis risk

Enhertu and its DXd cousins can inflame the lungs; combining them with immunotherapy, radiation, or mTOR inhibitors stacks that risk.

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.